Skinvisible Granted US Patent for Topical Drug Delivery Technology
Invisicare® Patent Protection Extends to Year 2029
Las Vegas, NV - December 4, 2012 - Skinvisible Pharmaceuticals, Inc. (SKVI: OTCQB) today announced that it has been granted US Patent Number 8,318,818 for methods of manufacturing its topical drug delivery technology, Invisicare®. The patent issued by the United States Patent and Trademark Office (USPTO) entitled "Topical Composition, Topical Composition Precursor, and Methods For Manufacturing and Using," will provide protection for Invisicare until February 2029. This is one of a series of three patents granted in the United States specifically protecting Invisicare. This patent is a divisional patent stemming from Skinvisible's main US patent and follows an announcement last week of the granting of a separate US patent for retinoids made with Invisicare.
This patent further protects the composition of Invisicare; a delivery technology used to bind active ingredients to the skin. Other key benefits include controlling the release of active ingredients and decreasing skin irritation. The patent covers a vast array of skin treatments including anti-acne, antifungals, anti-inflammatory, antimicrobials or any drug delivered to the skin with Invisicare. Additionally, skincare products such as anti-aging formulations, sunscreens and moisturizers have extended protection with the granting of this patent.
"The granting of this latest patent is fundamental to our intellectual property portfolio for Invisicare. Our products become highly desirable when you can provide new benefits to products and protect them from duplication in the marketplace as Invisicare can," said Terry Howlett, President and CEO. "Our patents increase the value of Skinvisible as a company and provide our potential licensees with a strong competitive position in the dermatology, skincare and topical drug marketplace." He added, "We expect our increased patent protection will assist us greatly in our discussions with potential licensees of our products."
Skinvisible's intellectual property portfolio for Invisicare includes: U.S.(3), Canada, Europe(4), Australia, India, Japan, China, Hong Kong and S. Korea along with three product specific US patents covering its dermal barrier products, sunscreen formulations and retinoids. Skinvisible is focused on strengthening its global patent portfolio with a number of patents pending for Invisicare as well as its forty plus prescription, over-the-counter and cosmeceutical formulations it has developed.